The Asia Pacific Molecular Quality Controls Market is expected to witness market growth of 6.7% CAGR during the forecast period (2022-2028).
The rising adoption of third-party quality controls, the growing number of credentialed clinical laboratories, the growing preference for external quality assessment support, declining sequencing costs, increasing government investment to support genomics projects, increasing demand for personalized medicines, and the rising prevalence of infectious diseases, cancer, and genetic diseases are all driving this Market forward.
The expanding number of licensed clinical laboratories, increasing usage of third-party quality controls, and increasing demands for external quality assessment help are some of the primary drivers driving the Molecular Quality Controls Market forward.
Due to the sheer rising demand for precise and high-quality diagnostics tests, the Asia Pacific molecular quality controls Market is in a solid position. With cancer becoming a more common health issue in the APAC region as a result of aging populations and lifestyle changes, the need for precision oncology has become a significant focus of various authorities in the region, prompting the creation of numerous projects. These initiatives include the K-MASTER (Korean Cancer Precision Medicine Diagnosis and Treatment Enterprise) platform in South Korea and the LC-SCRUM lung cancer genomic screening project in Japan.
Congenica, a diagnostic decision support platform provider, signed with Digital China Health Technologies Cooperation Limited (DCHealth) in September 2018 to launch a genomic drug in the Chinese Market. The rising use of tailored medications for disease treatment based on a patient's genetic information is predicted to boost the molecular quality controls Market in the future years
The China Market dominated the Asia Pacific Molecular Quality Controls Market by Country 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $18.6 million by 2028. The Japan Market is experiencing a CAGR of 6% during (2022-2028). Additionally, The India Market is expected to showcase a CAGR of 7.4% during (2022-2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
By Analyte Type
By Country
The rising adoption of third-party quality controls, the growing number of credentialed clinical laboratories, the growing preference for external quality assessment support, declining sequencing costs, increasing government investment to support genomics projects, increasing demand for personalized medicines, and the rising prevalence of infectious diseases, cancer, and genetic diseases are all driving this Market forward.
The expanding number of licensed clinical laboratories, increasing usage of third-party quality controls, and increasing demands for external quality assessment help are some of the primary drivers driving the Molecular Quality Controls Market forward.
Due to the sheer rising demand for precise and high-quality diagnostics tests, the Asia Pacific molecular quality controls Market is in a solid position. With cancer becoming a more common health issue in the APAC region as a result of aging populations and lifestyle changes, the need for precision oncology has become a significant focus of various authorities in the region, prompting the creation of numerous projects. These initiatives include the K-MASTER (Korean Cancer Precision Medicine Diagnosis and Treatment Enterprise) platform in South Korea and the LC-SCRUM lung cancer genomic screening project in Japan.
Congenica, a diagnostic decision support platform provider, signed with Digital China Health Technologies Cooperation Limited (DCHealth) in September 2018 to launch a genomic drug in the Chinese Market. The rising use of tailored medications for disease treatment based on a patient's genetic information is predicted to boost the molecular quality controls Market in the future years
The China Market dominated the Asia Pacific Molecular Quality Controls Market by Country 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $18.6 million by 2028. The Japan Market is experiencing a CAGR of 6% during (2022-2028). Additionally, The India Market is expected to showcase a CAGR of 7.4% during (2022-2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Analyte Type
- Single-analyte Controls
- Multi-analyte Controls
- Infectious Diseases Diagnostics
- Oncology Testing
- Genetic Testing
- Others
- Independent Controls
- Instrument-specific Controls
- PCR
- DNA Sequencing & NGS
- Others
- Diagnostic Laboratories
- Hospitals
- IVD Manufacturers & CROs
- Academic & Research Institutes
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Grifols, S.A
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Seegene, Inc.
- Randox Laboratories Limited
- F. Hoffmann-La Roche Ltd.
- Bio-Techne Corporation
- Microbiologics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Molecular Quality Controls Market by Analyte Type
Chapter 5. Asia Pacific Molecular Quality Controls Market by Application
Chapter 6. Asia Pacific Molecular Quality Controls Market by Product
Chapter 7. Asia Pacific Molecular Quality Controls Market by End User
Chapter 8. Asia Pacific Molecular Quality Controls Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Grifols, S.A
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Seegene, Inc.
- Randox Laboratories Limited
- F. Hoffmann-La Roche Ltd.
- Bio-Techne Corporation
- Microbiologics, Inc.
Methodology
LOADING...
